# BeyondSpring (stock symbol: BYSI) Logo in transparent PNG format

## BeyondSpring Logo large

### BeyondSpring Logo large Download PNG (54.62 KB)

![BeyondSpring Logo large Download PNG (54.62 KB)](/img/orig/BYSI_BIG-ef15749e.png)

## BeyondSpring Logo icon format

### BeyondSpring Logo icon format Download PNG (120.2 KB)

![BeyondSpring Logo icon format Download PNG (120.2 KB)](/img/orig/BYSI-66e7375c.png)

## About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

1. Website domain: beyondspringpharma.com
2. Employees: 103
3. Marketcap: $37.69 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
